

CONTENTS

	Page
ACKNOWLEDGEMENTS	i
ABSTRACT	ii
CONTENTS	vi
LIST OF TABLES	xiii
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xviii
 CHAPTER	
I INTRODUCTION	1
II OBJECTIVES	5
III LITERRATURES REVIEW	6
1. Epidemiology	6
2. Malaria	9
3. The malaria parasite and its life cycle	9
4. Drug resistance in malaria parasites	11
4.1 WHO classification of clinical response or resistance to antimalarial drugs	13
5. Control of malaria	16
5.1 Introduction	16
5.2 Vector control	16
5.3 Health education and primary health care	17
5.4 Malaria vaccine development	17
5.5 Antimalarial chemotherapy	19
5.5.1 4-aminoquinoline	23
5.5.1.1 Inhibition of malarial pigment formation	23
5.5.2 The new generation of antimalarial drug	27

CONTENTS (Cont.)

	Page
5.6 New antimalarial drug targets	32
6. The emergence and spread of quinoline resistance	33
6.1 Cross-resistance patterns of antimalarials	35
6.2 Determinants of antimalarial drug resistance	36
6.3 Mechanisms of quinoline resistance	36
7. Molecular basis of quinoline resistance	40
7.1 PfCRT	40
7.1.1 PfCRT and biochemical models of chloroquine resistance	44
7.1.1.1 Energy-coupled CQ efflux	47
7.1.1.2 Leak of charged chloroquine out of the digestive vacuole	48
7.1.1.3 pH-dependent physiological changes at the digestive vacuole membrane	49
7.2 PfMDR1	49
7.3 Other transporters implicated in antimalarial drug resistance	53
8. History of national drug policy of Thailand	54
IV MATERIALS AND METHODS	58
1. Culture system for parasite maintenance	58
1.1 Culture medium	60
1.2 Preparation of uninfected erythrocytes	60
1.3 Serum	60
1.4 Gas phase	61
1.5 Parasite cultivation	61

CONTENTS (Cont.)

	Page
1.6 Monitoring of culture parasitaemia	62
1.7 Synchronisation of parasite culture	62
1.8 Cryopreservation and retrieval of parasite culture	63
2. <i>In vitro</i> drug sensitivity assay	63
2.1 Preparation of drug solutions	64
2.2 Preparation of parasite inoculum	64
2.3 Preparation of [³ H] hypoxanthine	64
2.4 <i>In vitro</i> sensitivity assay	64
2.5 Harvesting of microtitre plate	65
2.6 Scintillation counting	65
2.7 Data analysis	65
3. Polymerase chain reaction	66
3.1 Preparation of parasite DNA	66
3.1.1 Saponin lysis of parasitised erythrocytes	66
3.1.2 Extraction of parasite DNA	66
3.1.3 Determination of the amount of DNA by Spectrophotometry	66
3.2 Nested PCR and restriction enzyme digestion for the detection of polymorphisms in <i>pfcr1</i>	67
3.2.1 Codon 76	67
3.2.2 Codons 220 and 271	67
3.2.3 Codons 326, 356 and 371	67
3.3 Nested PCR and restriction enzyme digestion for the detection of polymorphisms in <i>pfmdr1</i>	72
3.4 Agarose gel electrophoresis	76
3.5 Detection of gene copy number of <i>pfmdr1</i>	76

CONTENTS (Cont.)

	Page
3.6 Statistical analysis	79
V RESULTS	80
1. <i>In vitro</i> drug susceptibility of <i>P. falciparum</i> isolates	80
1.1 CQ susceptibility	80
1.2 QN susceptibility	84
1.3 MQ susceptibility	87
1.4 ARS susceptibility	91
2. <i>In vitro</i> cross resistance	94
3. Genetic polymorphisms of <i>P. falciparum</i> isolates	94
3.1 <i>Pfcr</i> t polymorphisms	94
3.2 <i>Pfmdr</i> 1 polymorphisms	104
4. Association between polymorphisms of <i>pfcr</i> t and <i>pfmdr</i> 1 genes and time periods of isolates collection	111
4.1 Polymorphisms of <i>pfcr</i> t gene	111
4.2 Polymorphisms of <i>pfmdr</i> 1 gene	111
5. Association between gene copy numbers of the <i>pfmdr</i> 1 gene and time periods	111
6. Association between gene copy numbers of the <i>pfmdr</i> 1 gene and the <i>in vitro</i> susceptibility	113
6.1 Association between the gene copy numbers and allelic polymorphisms of the <i>pfmdr</i> 1 gene and <i>in vitro</i> drug susceptibility.	113
6.1.1 Codon 86	113
6.1.2 Codon 184	116
6.1.3 Codon 1034	118
6.1.4 Codon 1042	121

CONTENTS (Cont.)

	Page
6.1.5 Codon 1246	124
6.2 Multiple point mutation of <i>Pfmdr1</i> gene	126
6.3 Determination of the molecular markers influencing <i>in vitro</i> drug susceptibility level.	134
VI DISCUSSIONS	137
1. <i>In vitro</i> drug susceptibility of <i>P. falciparum</i> isolates to quinoline-containing antimalarials and artesunate	137
1.1 CQ susceptibility	137
1.2 QN susceptibility	137
1.3 MQ susceptibility	138
1.4 ARS susceptibility	138
2. <i>In vitro</i> cross resistance	139
3. Association between genetic polymorphisms of <i>pfcr1</i> and <i>pfmdr1</i> with period of time	139
3.1. <i>pfcr1</i> polymorphism	139
3.2. <i>pfmdr1</i> polymorphism	140
3.3. <i>pfmdr1</i> gene copy number and time periods	141
4. Association between gene copy number, allelic polymorphisms of the <i>pfmdr1</i> gene and the <i>in vitro</i> susceptibility	141
4.1. CQ	141
4.2. QN	143
4.3. MQ	144
4.4. ARS	145

CONTENTS (Cont.)

	Page
VII CONCLUSIONS	147
1. <i>In vitro</i> drug susceptibility of <i>P. falciparum</i> isolates to quinoline-containing antimalarials and artesunate	147
1.1 CQ susceptibility	147
1.2 QN susceptibility	147
1.3 MQ susceptibility	147
1.4 ARS susceptibility	147
2. <i>In vitro</i> cross resistance	147
3. Association between genetic polymorphisms of <i>pfcr</i> and <i>pfmdr1</i> with period of time	148
3.1 <i>pfcr</i> polymorphism	148
3.2 <i>pfmdr1</i> polymorphism	148
4. Association between gene copy number and time periods	148
5. Association between gene copy number, allelic polymorphisms of the <i>pfmdr1</i> gene and the <i>in vitro</i> susceptibility	148
5.1. CQ	148
5.2. QN	148
5.3. MQ	148
5.4. ARS	149
REFERENCES	150
APPENDIX A	181
APPENDIX B	185
APPENDIX C	187

CONTENTS (Cont.)

	Page
BIOGRAPHY	191